The ongoing lack of therapies to address schizophrenia’s negative and cognitive symptoms presents a key commercial opportunity for drug developers.
By Inês Guerra, Analyst
18 March 2016
I joined Datamonitor Healthcare as an analyst in early 2015, having completed a Master’s degree in Pharmaceutical Scie...
Read full bio
While currently approved antipsychotics manage schizophrenia’s positive symptoms adequately, other symptom domains are lacking effective treatment options. Datamonitor Healthcare’s survey of 236 psychiatrists across the US, Japan and five major EU markets (France, Germany, Italy, Spain, and the UK) revealed that generic oral antipsychotics remain the backbone of schizophrenia treatment practices, across all surveyed markets.
Despite dominating current treatment practices, these well-established drugs have not been proven to address negative or cognitive symptoms. Surveyed psychiatrists actually rated treatments for negative symptoms as schizophrenia’s greatest unmet need, seeing as they are present in nearly 50% of all schizophrenia patients and remain largely untreated – despite contributing extensively to the overall disease burden.
Other identified key unmet needs included additional options for treatment-resistant patients, and treatments for cognitive symptoms. As the schizophrenia market is becoming increasingly genericized, new drugs will require clear differentiating features to succeed – and the key opportunities for companies lie in the development of drugs to address the disease’s unmet needs.
Datamonitor Healthcare’s Schizophrenia: Treatment reveals how schizophrenia patients are currently managed, and which are the disease’s greatest unmet needs.
Register for a free demo to find out more information on our latest Schizophrenia: Treatment report >>>
If you are a current subscriber you can view our Schizophrenia treatment report here
Posted in Latest Research.